Facebook

Twitter

Linkedin

Email

Print

Belantamab mafodotin is an experimental antibody-drug conjugate that targets B-cell maturation antigen that initially showed activity as a single agent in relapsed/refractory multiple myeloma.

In clinical trials, the safety profile of belantamab mafodotin appeared manageable, but keratopathy—characterized as changes in the corneal epithelium observed by ophthalmic examination, which can manifest with or without symptoms—was the most common treatment-related adverse event. 

Charles W. Nichols, MD, associate professor of ophthalmology and deputy chief of ophthalmology for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discussed best practices for managing ocular toxicities associated with belantamab mafodotin, including symptoms management options, care coordination with the patient’s hematologist/oncologist, and more.

Read More

Facebook

Twitter

Linkedin

Email

Print

Credit: Original article published here.